Skip to main content
Clinical Trials/NCT07320872
NCT07320872RecruitingNot Applicable

Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris and Its Relation to Pathogenesis and Risk of the Disease

Aswan University1 site in 1 country60 target enrollmentStarted: August 10, 2025Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
60
Locations
1
Primary Endpoint
Detection of vaspin gene polymorphism

Study Overview

Brief Summary

Psoriasis is a common immune-mediated inflammatory skin disease affecting at least 100 million individuals worldwide. In Egypt, the prevalence of psoriasis ranges between 0.19% and 3% of the Egyptian people.

It is associated with poor quality of life, reduced life expectancy and multimorbidity including psoriatic arthritis, obesity and cardiovascular disease.

Vaspin (VASP, SERPIN 12) is a recently discovered adipokine that has been isolated from the visceral adipose tissue of a rat model of type 2 diabetes. It is coded by the gene SERPNA12 located on the long arm of chromosome 14q32.13 and consists of six exons and five introns.

Detailed Description

Psoriasis can present at any age. However, the disease onset appears to follow a bimodal distribution, peaking around 20-30 years of age and again around 50-60 years of age.

Psoriasis is a common skin disease characterized clinically by formation of erythematous and scaly plaques at different sites affecting mainly the extensor prominences, scalp, the lumbosacral area and the sites of trauma. It is a lifelong disease with spontaneous remissions and exacerbations.

The exact etiology is unknown, but it is considered to be an autoimmune disease mediated by T lymphocytes. It is considered the most prevalent T-cell-mediated inflammatory disease in human beings, in which, keratinocytes in focal skin regions are stimulated to proliferate with activation of the immune system mediated by primed T-lymphocytes.

There is an association of HLA antigens seen in many psoriatic patients, particularly in various racial and ethnic groups. Familial occurrence suggests its genetic predisposition .

The pathophysiology of psoriasis involves infiltration of the skin by activated T cells which stimulate the proliferation of keratinocytes. This dysregulation in keratinocyte turnover results in the formation of thick plaques. Other associated features include epidermal hyperplasia and parakeratosis. There are several treatment options available for mild psoriasis, including topical corticosteroids, vitamin D analogs, calcineurin inhibitors, keratolytics, and targeted phototherapy.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Newly diagnosed cases or stopped treatment of at least 6 months of psoriasis patients.
  • Pateints with any age and gender.

Exclusion Criteria

  • Pregnancy and lactation.
  • Patients with chronic diseases: cardiac diseases, hepatic disorders, chronic renal failure or malignancies.
  • Patients with associated inflammatory disease such as infections and autoimmune diseases.

Arms & Interventions

Group A: Psoriasis Patients

About 30 patients suffering from Psoriasis Vulgaris will subject to vaspin gene polymorphism measure and Assessment of the disease severity will be performed by using Psoriasis area and severity index score (PASI score) for all patients.

Intervention: vaspin gene polymorphism (Biological)

Group B: Control Group

About 30 healthy participants will share as A control Group

Intervention: vaspin gene polymorphism (Biological)

Outcomes

Primary Outcomes

Detection of vaspin gene polymorphism

Time Frame: 12 Months

Assessment of vaspin gene polymorphism in psoriasis patients to determine the disease severity

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ola Mahmoud Elqousy

Specialist at Dermatology, Venereology and Andrology Department

Aswan University

Study Sites (1)

Loading locations...

Similar Trials